Background: There is debate about the accuracy of anal cytology and high-resolution anoscopy
INTRODUCTION
Anal cancer incidence has increased substantially in recent decades, and is highest among HIVinfected men who have sex with men (MSM), other people with HIV and other causes of immunosuppression, and women with previous human papillomavirus (HPV)-related anogenital disease (1) (2) (3) . As with cervical cancer, anal cancer is largely caused by high risk (HR) types of HPV (HR-HPV), particularly HPV16, and it is preceded by anal high-grade squamous intraepithelial lesions (HSIL) (4, 5) .
There is no clear agreement about the efficacy of screening and treatment of precursor lesions to prevent anal cancer (6) . For cervical cancer, locations with population-based screening programs have seen a dramatic decline in cervical cancer incidence and mortality (7) . Screening programs include cervical cytology (Papanicolaou (Pap) test), referral of women with abnormalities for colposcopy, and treatment of histologically-proven cervical HSIL. Some researchers have advocated that a similar cytology-based screening and treatment program should be adopted for anal HSIL (8) .
However, the test performance of anal cytology continues to be debated (9) . In particular, in order to achieve similar sensitivity to cervical screening, a lower abnormality threshold for referral for the diagnostic test (high resolution anoscopy (HRA)-guided biopsy) is recommended by some (5) . Partly because of the lower threshold for referral, anal cytology is generally less specific than cervical screening (5, 9) . Additionally, the diagnostic test, HRA-guided biopsy, is acknowledged as technically more difficult than cervical colposcopy and is therefore more likely to miss HSIL lesions, particularly if the anoscopist is relatively inexperienced with the procedure (10) . Given this, some have suggested that the results of both the anal cytology and the HRA may be necessary to obtain an accurate measure of true anal HSIL burden (11, 12) .
To compare the separate and combined diagnostic accuracy of anal cytology and histology on HRAguided biopsy, population-based studies that perform both tests on the same individuals at the 4 same visit are required. However, only a handful of such studies has been reported (6, (13) (14) (15) , perhaps because of reluctance to perform a relatively invasive procedure such as HRA in the entire at-risk population. We examined baseline data from a predominantly community-based cohort of homosexual men, in which both tests were performed on all participants at the same clinical visit.
We evaluated categories of anal squamous intraepithelial lesion (ASIL) severity by examining the prevalence of the causative organism HPV16 and other HR-HPV in separate and combined categories of cytology and histology results.
MATERIALS AND METHODS

Study population
The Study of Prevention of ANal Cancer (SPANC) is an ongoing prospective study of HIV-positive and HIV-negative homosexual men aged 35 years and older, based in Sydney, Australia. Participants were recruited mainly from community-based settings. About 35% of HIV positive and 5% of HIV negative men were recruited through medical clinics. The study was approved by the St Vincent's Hospital Ethics Committee (Sydney, Australia) and all participants gave written informed consent.
The study protocol and the study's main objectives have been described in detail previously (16) .
HPV detection, anal cytology and HRA
The clinical and laboratory procedures performed in this study have been described in detail previously (16) . In brief, a saline-moistened Dacron swab was inserted 3-5 cm into the anal canal without direct visualisation, and then gradually withdrawn while applying firm circumferential pressure to the wall of the anal canal for approximately one minute. The swab was then agitated in a vial containing PreservCyt (Hologic Corporation, Bedford, MA, USA). Prior to cytological processing, an aliquot of the medium was transferred to a separate tube for HPV testing. The remaining sample was used for preparation of a slide for cytological analysis. If the anal swab was deemed unsatisfactory for cytological evaluation, a repeat anal collection was performed no less than two weeks from the first. This minimum time requirement was to allow sufficient time for the anal mucosal cells to regenerate after the initial swab. A 'satisfactory' slide was defined as having at least 2000 nucleated squamous cells.
The HRA was performed immediately after the anal swab in a manner similar to established techniques of applying acetic acid (3% initially (16) , but changed in January 2015 to 5% in response to evolving opinion that the higher concentration may allow better visualization of SIL (10) visualization using a colposcope on high magnification as published (10, 16) . Following insertion of a plastic anoscope and application of 5% acetic acid the anal canal was visualised under highresolution magnification with further application of acetic acid, followed by Lugol's iodine, to identify any abnormalities. Any abnormalities which were visually suggestive of ASIL were biopsied for histological assessment. Men who had no visual abnormalities did not undergo biopsy.
The samples were transferred to a pathology laboratory (Douglass Hanly Moir Pathology, Sydney, Australia) for processing and assessment. Reporting of cytology and biopsy results were performed according to The Bethesda System TBS (17) and in accordance with criteria, terminology and recommendations of the Lower Anogenital Squamous Terminology (LAST) Project (18), respectively, as described previously (14) . In particular, when a diagnosis of HSIL-AIN2 was proposed, immunostaining for p16 INK4A (p16) was performed and only those with strong uniform staining of the basal layer were considered positive and thus given the diagnosis of HSIL-AIN2. If the result was negative, the lesion was downgraded to LSIL or negative for SIL, depending on other criteria. If multiple biopsies were taken, the result with the highest grade of disease was used for analysis.
HPV PCR amplification and reverse line blot detection were performed on the anal PreservCyt specimens using the Roche LINEAR ARRAY (Roche Molecular Systems, Alameda, CA, US) detect 37 individual HPV types with modifications as previously described (16, 19) . As an in-house modification, samples that were negative for HPV and internal control were retested with half the volume of eluted DNA in order to reduce the inhibition due to high bacterial DNA content.
Statistical analysis
We examined the prevalence of individual cytology and histology SIL categories, and the prevalence of HPV16 and other HR-HPV types (not including HPV16) within these categories. Within each histological category, we calculated HPV16 and other HR-HPV prevalence in strata of cytological result. In addition, within each cytological category, we calculated HPV16 and other HR-HPV prevalence in strata of histological result. We then constructed composite cytology-histology endpoints based on increasing prevalence of HPV16. Figure 1 and Table 2 ). The prevalence of HPV16 and other HR-HPV types (not including HPV16) was 25.9% and 33.3% respectively, in men with repeatedly unsatisfactory smears.
For histologically defined endpoints, the prevalence of HPV16 was 17.4% in men with normal appearance (no biopsy taken) and 17.6% in men with no ASIL on biopsy. This increased to 22.7%, 24.5% and 60.1% (p-trend <0.001) in men with LSIL, HSIL-AIN2 and HSIL-AIN3 histology respectively.
The prevalence of other HR-HPV types was increased in men with HSIL-AIN2 (p=0.002), but overall the prevalence did not change across increasing histological grade (p-trend=0.568) as above ( Figure   1 and Table 2 ).
To assess the potential value of combining cytology and histology results to improve the accuracy of HSIL detection, the prevalence of HPV16 and other HR-HPV types was analysed in men with histological disease endpoints. HPV prevalence was then analysed within each histological group, stratified by the results of their corresponding cytology diagnosis, as follows ( Figure 2 and Table 2 ).
Among 263 men with no histological ASIL, the prevalence of HPV16 and other HR-HPV types was Next, the prevalence of HPV16 and other HR-HPV types was examined in men within each cytological result, stratified by their corresponding histology diagnosis, as follows ( Figure 3 and Table   2 ). Among 27 men with unsatisfactory cytology results the prevalence of HPV16 increased significantly from 13.3% in men with negative histology to 75.0% in men with HSIL histology (p- Table 2 ).
Thus, for each category of cytology, except HSIL, increasing grade of histological result was associated with a higher HR-HPV prevalence (HPV16 and other HR-HPV types), but this difference did not always reach statistical significance. When the cytology result was HSIL, increasing grade of histology was associated with a significantly higher prevalence of HPV16 and a lower prevalence of other HR-HPV types.
Definition of composite endpoints based on positive cytology or histology results
Given the significant association between composite cytology-histology endpoints and HPV16, four composite endpoint outcomes were constructed, representing categories of increasingly close association with HPV16 (Table 3) .
First, we defined a "composite-negative" category which included men who were negative for ASIL by both cytology and histology. Men with unsatisfactory cytology results who had normal histology were also included in this category, as the prevalence of HPV16 and other HR-HPV types was similar between the two groups. Almost one-third (29.9%, 95% CI: 26.3-33.7) of men in the SPANC cohort were in the composite-negative category. The prevalence of HPV16 and other HR-HPV types in men in this category was 12.1% and 27.6%, respectively. HPV16 prevalence in this composite category was lower than in either men with negative cytology or men with normal/negative histology endpoints considered separately. In addition, the prevalence of any HPV was lower in this group (Table 2- Third, we defined a "composite-HSIL" category which included men who had HSIL detected by either cytology and/or histology. Over one-third (37.7%, 95% CI: 33.8-41.7) of men were in this category.
The prevalence of HPV16 and other HR-HPV types was 50.0% and 39.0%, respectively. Within this category, we sub-categorized HSIL as "composite-AIN2" (HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either) and "composite-AIN3" (HSIL-AIN3 on either cytology or histology) with prevalence of 8.4% (95% CI: 6.3-10.9) and 29.3% (95%CI: 25.6-33.1), respectively.
The prevalence of HPV16 in men with composite-AIN3 (58.2%) was more than twice that of men with composite-AIN2 (21.6%, p=0.002), whereas the prevalence of other HR-HPV types was significantly lower in men with composite-AIN3 (32.8%) than in men with composite-AIN2 (60.8%, 
p=0.005). The prevalence of HPV16 in this composite category was comparable to that of HSIL cytology and HSIL histology endpoints considered separately. Of note, the prevalence of LR-HPV types in the absence of detection of HR-HPV types decreased significantly with increasing grade of composite-endpoint (p-trend<0.001) (Table 2-3) .
Fourth, we defined a remaining category of men who had ASC-H reported on cytology and who had less than HSIL on histology. About one in 12 men (7.4%, 95% CI: 5.5-9.8) were in this "composite-ASC-H" category. The prevalence of HPV16 and other HR-HPV types in men in this category was 31.1% and 42.2%, respectively and lay between those among men with composite-LSIL and men with composite-HSIL ( Table 2-3) .
Lastly, we examined the association between HPV-16, other HR-HPV types and LR-HPV only and increasing grade of composite endpoints by HIV status. Identical patterns to that seen in the overall study population were observed (Supplementary Table S1 ).
DISCUSSION
In this study of predominantly community-recruited homosexual men undergoing anal cytology and HRA at the same clinical visit, the prevalence of cytologically predicted HSIL (18%) was substantially lower than that found on HRA-guided biopsy (32%). The use of a composite endpoint comprising either a cytological and/or histological diagnosis further increased HSIL prevalence to 38%.
Composite-HSIL appeared to be a biologically meaningful category, with a very similarly high prevalence of HPV16 and other HR-HPV types (89% overall, with 50% HPV16 and 39% other HR-HPV) to that seen when histological HSIL (90% overall, with 51% HPV16 and 39% HR-HPV) or cytological HSIL (91% overall, with 59% HPV16 and 31% other HR-HPV) were seperately considered. Lower absence of HR-HPV infection. Given the assocation of increasingly high prevalence of HPV16 across increasing grades of composite disease endpoint, these composite endpoints appear to represent biologically meaningful measures of significant HPV-related ASIL. The increased prevalence of HSIL found using the composite endpoint, combined with its strong relationship with HPV16, provides a rationale for using, where possible, composite cytology-histology endpoints in studies of the prevalence and risk factors for anal HSIL.
Our estimate of composite-HSIL prevalence was higher than the prevalence of biopsy proven HSIL in the previous meta-analysis (6) . This most likely reflects the improved sensitivity of a composite endpoint to detect HSIL compared to histology used alone. Composite cytology-histology endpoints have been applied in very few previous studies of ASIL. In three prospective studies, composite endpoints were reported in a subset of participants and visits (20) (21) (22) . Only one study has previously reported composite cytology-histology endpoints on the entire population (13, (23) (24) (25) . In that crosssectional report of 363 HIV-positive MSM recruited from an anal cancer screening clinic in San Francisco, the prevalence of HSIL was 18% (95% CI: 14%-22%) using cytology alone, 22% (95% CI: 18%-27%) using histology alone, and 30% (95% CI: 26%-36%) using a composite cytology and/or histology endpoint (23) . The prevalence of HPV16 of 55% (23) in participants with composite-HSIL was strikingly similar to our finding (50%). However, a higher prevalence of histologically proven HSIL (32%) was observed in our study, resulting in a higher composite endpoint prevalence. A possible reason for the higher HSIL prevalence is that in the San Francisco study a maximum of two biopsies was performed (13) , whereas in SPANC the number of biopsies was not limited, and in fact 28% of men had more than two biopsies taken. In addition, participants in SPANC reported higher levels of sexual risk behavior. In SPANC nearly all men (98%) reported five or more lifetime male partners compared to 83% in the San Francisco study (13) . This may have contributed to greater HR-HPV exposure and hence higher HSIL prevalence in our study. AIN2 (22%) was less than half than that seen in men with composite-AIN3 (58%, p=0.002). A similar, but less marked differential was seen in the San Francisco study (47% versus 61%) (23) . Considering a large majority of anal cancers are caused by HPV16 (26) , this suggests that the composite-AIN3 category more accurately represents true 'anal precancer' than the composite AIN2 category, as is the case in the cervix (27) . In a recent Australian study of 112 anal cancer samples analysed for the presence of HPV DNA, 108 (96%) were HPV DNA positive and, of those, 81 (75%) were positive for HPV16 (28) .
Although the grouping of cytology-histology endpoints in this study was guided by HPV16 prevalence, it must be acknowledged that there are many other potential groupings of composite endpoints. Our groupings are similar to those published by the San Francisco study (25) , except in one regard: we created an additional category of men with ASC-H on cytology, but no HSIL on histology. We did this because this cytology-histology endpoint had a HPV16 prevalence (31%) which was clearly intermediate between that seen in composite-LSIL (19%) and composite-HSIL (50%).
Limited data suggests that in women with cervical ASC-H who go on to have a normal or LSIL histology result at colposcopy, the risk of underlying HSIL may be substantial. In a prospective cohort study of 53 women with cervical ASC-H who underwent initial colposcopy without treatment, 24 (45%) were diagnosed with HSIL histology at follow-up (29). In the cervix, ASC-H is uncommon, accounting for approximately 0.2%-0.5% of cytological results (30, 31) . In published studies, the prevalence of ASC-H in the anal canal is substantially higher (2-11%) (6, 23) than in the cervix and in SPANC was 14%. In this study, of all men with ASC-H cytology, 48% had HSIL histology ( Table 2) endpoints accrues, we will be able to make more definitive conclusions about the accuracy of the composite-HSIL diagnoses and their natural history. Second, the small sample size in some cytologyhistology combinations limits the statistical power of the analysis. However, the statistically significant pattern of HPV16 detection supports the validity of the findings, and our report is almost double the size of the largest previous report of a combined cytology-histology endpoint. Third, although our anoscopists were well trained (16), most were relatively new to the field and it is possible that their performance in diagnosing HSIL at HRA will improve further with time. However, when we stratified baseline study visits by the degree of experience of the anoscopist, we found that the additional HSIL prevalence afforded by the composite endpoint was virtually identical between most-and lesser-experienced anoscopists (data not presented). In a Dutch study, it has been reported that the diagnostic yield of HRA increases until an operator has performed approximately 200 HRAs [32] . Fourth, it is important to note that HPV genotyping was performed on the ThinPrep aliquat collected prior to cytological processing, and not on lesional tissue. Hence, in some instances, if the anal cytology missed an HSIL lesion during sampling, the associated (causative) HPV type may have also been missed. Given the high burden of HPV in this population, including the presence of multiple HPV types (33) and the concurrent presence of multiple lesions (of which the highest grade was taken as the endpoint), it cannot be inferred that the diagnosed lesions were definitely caused by the HPV types detected.
SPANC is one of only a small number of cohort studies globally and the largest published thus far, to perform anal cytology and HRA screening, as well as HPV genotyping at the same visit on all participants, with no limitation on the number of biopsies allowed. In addition, recruitment for the study was mostly from community-based settings with broad inclusion criteria, making the results more generalisable to a target screening population. Biopsy reporting was performed in accordance with the LAST Project recommendations (16, 18) , limiting potential misclassification of histological HSIL. There was a very high degree of inter-rater reliability and intra-rater repeatability in 
histological diagnosis in the study (34) . This study demonstrates that epidemiological studies of HSIL may underestimate the prevalence of HSIL if the results of anal cytology and HRA are not combined, and highlights the limitations of both techniques. Studies on the performance of anal cytology in detecting histologically proven HSIL in homosexual and bisexual men demonstrate that the procedure clearly underestimates the true prevalence of HSIL (35) . HRA is also prone to considerable sampling and measurement error, and is much more technically demanding than cervical colposcopy (10). However, it has to be recognised that performing anal cytology and HRA on all participants, in epidemiological studies and in clinical practice, will often not be practical, because HRA is an invasive and resource-intensive procedure.
Research should focus on optimising anal cytology sampling protocols to improve HSIL detection.
Incorporating HPV and molecular biomarkers may prove useful in increasing the yield and diagnostic accuracy of anal cytology and targeting HRA to those most likely to have HSIL. It is also important to note, while composite endpoints may be useful in studies of HSIL prevalence to identify cases which are missed at HRA, they are not a substitute for HRA performed by well-trained individuals.
Advanced training in HRA and attention to quality assurance programs, similar to those in cervical colposcopy [36] is likely to improve the diagnostic yield of HRA. When HRA is performed by the most experienced hands, composite endpoints may provide smaller additional benefit.
In summary, diagnosis of ASIL has been hindered by the limited sensitivity of both anal cytology sampling and HRA used alone. As a result, many published studies of cytology-only and histologyonly ASIL endpoints likely underestimate the true prevalence of HSIL. This study has demonstrated that combining the results of anal cytology and HRA leads to the diagnosis of more biologically relevant disease. Until data on biomarkers that will improve diagnostic accuracy of cytology are available, epidemiological studies of anal HSIL risk should, where possible, include data on composite cytology and histology endpoints in order to improve the sensitivity of ASIL detection. 
